Clips are often placed to mark axillary nodes with biopsy-confirmed metastases in patients with breast cancer. The evaluation of clipped nodes after chemotherapy can identify patients who have eradication of nodal disease. The goal of this study was to determine whether preoperative fine-needle aspiration (FNA) of clipped nodes after neoadjuvant chemotherapy (NAC) could predict the presence of residual disease. METHODS: This prospective registry study enrolled 50 patients with a clip placed to mark nodes with biopsy-confirmed metastases who had completed NAC. Participants underwent FNA of the clipped node before seedlocalized lymph node excision. FNA pathology was compared with surgical pathology. RESULTS: There were 36 patients (72%) with residual disease on surgical pathology: 3 (8%) had a nondiagnostic aspirate, carcinoma was seen in 14 (39%), and 19 (53%) had a false-negative result. The sensitivity of FNA was 42.4%, its specificity was 100%, and its negative predictive value was 40.6%. In a univariate analysis, the odds of a true-positive result increased significantly with the mean initial size of the clipped node (odds ratio [OR], 4.3; P = .004) and the size of the metastatic focus after NAC (OR, 1.3; P = 0.003), whereas normalization of nodes after chemotherapy (OR, 0.1) and a lack of response on ultrasound (OR, 0.11) were associated with a false-negative result (P = .01). CONCLUSIONS: FNA of marked nodes after chemotherapy has a high false-negative rate. This highlights the need for surgical staging of the axilla after NAC to assess the response. Cancer 2019;125:365-373.
INTRODUCTION
The status of axillary lymph nodes is an important prognostic feature in patients with breast cancer. Because of the impact of nodal disease on management, ultrasound is often used to evaluate newly diagnosed patients. Suspicious lymph nodes identified by ultrasound can be biopsied to assess for metastases. Fine-needle aspiration (FNA) enables immediate onsite assessment and real-time staging, which expedite treatment planning. [1] [2] [3] This approach has superior sensitivity in comparison with ultrasound alone or a physical examination. 2, 4 Advocates of nodal ultrasound with FNA point to potential cost savings because unnecessary surgical staging procedures, specifically sentinel lymph node dissection (SLND), can be omitted if metastases are identified preoperatively. 5, 6 Patients with pathologically confirmed nodal metastases often receive neoadjuvant chemotherapy (NAC), which can result in conversion to a pathologically node-negative status in 21% to 75% of patients according to the tumor subtype. 7, 8 Historically, patients with proven nodal metastases have required completion axillary lymph node dissection (ALND) after chemotherapy, regardless of the response. However, recent trials have opened consideration for minimally invasive surgical techniques. The American College of Surgeons Oncology Group (ACOSOG) Z1071 trial was designed to determine whether SLND could accurately assess nodal responses after NAC and thus identify patients who could potentially avoid ALND. 9 Although the reported false-negative rate (FNR) of 12.6% exceeded the prespecified success threshold of 10%, an interesting observation was made in subsequent analyses. In 170 patients, a clip was placed to mark the node with biopsy-confirmed metastases before chemotherapy. When this clipped node was retrieved as a sentinel lymph node (SLN; n = 107), the FNR of SLND was lowered to 6.8%. 10 The utility of evaluating the
Cancer February 1, 2019 clipped node specifically was confirmed in a subsequent single-institution registry trial that reported an FNR of 4.2% for the evaluation of the clipped node after NAC. 11 An assessment of the node known to initially contain metastasis is a logical step in axillary staging and has been incorporated into National Comprehensive Cancer Network guidelines. 12 There are now reports of surgical techniques such as targeted axillary dissection, which ensures removal of the clipped node along with SLND, showing FNRs as low as 2%, and this demonstrates that an evaluation of the clipped node is critical to an axillary assessment after NAC. 11, 13 Although the use of SLND and techniques ensuring removal of the clipped node are gaining acceptance, 14 all of these approaches require preoperative procedures such as injections or the placement of seeds as well as surgical staging. The identification of residual nodal metastases still requires ALND unless the patient is enrolled in a clinical trial that dictates a different therapy. Preoperative identification of residual disease would allow for improved surgical planning for completion ALND when indicated without the unnecessary procedures and expense required for SLND or the marking and removal of clipped nodes. Because the node with confirmed metastasis can be marked and followed through chemotherapy, there is potential use for FNA, which has been proven to be sensitive and specific in the prechemotherapy setting, after the completion of NAC to assess the response. However, there are currently no data concerning the accuracy of FNA of axillary nodes in the post-NAC setting. The goal of this study was to determine whether FNA of the clipped lymph node could reliably identify residual nodal disease after NAC.
MATERIALS AND METHODS

Study Design
This prospective study was conducted between 2014 and 2017 with approval from the institutional review board. To be eligible for enrollment, patients had to have biopsyproven axillary node metastasis with a clip placed in the node at the time of biopsy, have completed NAC, and be scheduled for seed-localized excision of the clipped node at the time of surgery. Eligible patients were enrolled after they had signed an informed consent form.
Study Protocol
According to our institutional standard, all patients underwent routine imaging with mammography and ultrasound of the breast and regional nodal basins at the time of diagnosis. Nodes with an abnormal appearance on ultrasound because of either size or morphology 2 were biopsied with a 21-gauge needle and stained with the Papanicolaou and Diff-Quik methods, with an onsite evaluation performed by a dedicated breast cytopathologist. 1 The diagnosis of carcinoma was based on the presence of features such as an enlarged nucleus, nuclear membrane irregularities, a prominent nucleolus, scant or moderate amounts of delicate or vacuolated cytoplasm, and mitotic figures in tumor cells. If more than 1 abnormal node was seen, the most suspicious node was biopsied. If nodal metastasis was confirmed pathologically, a clip was placed in the biopsied node. All enrolled patients received anthracycline-and/or taxane-based chemotherapy regimens. Patients with human epidermal growth factor receptor 2 (HER2)-positive tumors had additional HER2-targeted therapy.
After the completion of chemotherapy, the surgical approach was determined by the treating breast surgical oncologist. To localize the clip-containing lymph nodes intraoperatively, patients had ultrasound-guided I 125 radioactive seed placement in the clipped lymph node up to 5 days before surgery. Trial participants underwent FNA with a 21-gauge needle under ultrasound guidance during this encounter before the seed was placed. A sample was considered nondiagnostic if no cellular tissue (either lymphoid or carcinoma) was seen in the aspirate.
During surgery, the clip-containing nodes were removed separately and sent for intraoperative radiography. All enrolled patients had a seed and clip identified in the specimen. The nodes were serially sectioned and processed with routine hematoxylin-eosin staining with the addition of pancytokeratin staining at the discretion of the pathologist. Any residual metastatic focus, including isolated tumor cells, was considered node-positive.
Data Analysis
Data were analyzed with R 3.3.1. 15 The association between categorical variables and clinical outcomes was assessed with the Fisher exact test. Continuous variables were assessed with the unequal variance t test. Among patients with residual disease, logistic regression was used to evaluate clinical and imaging characteristics for associations with the occurrence of a true-positive biopsy result. Firth penalized logistic models were fitted for covariates with zero-count cells. All statistical tests used a significance level of .05.
Cancer February 1, 2019 RESULTS Fifty patients were enrolled. The clinicopathologic features of the participants are summarized in Table 1 . Twenty-one patients (42%) had 1 abnormal node on the initial pretreatment ultrasound, 9 (18%) had 2 abnormal nodes, 8 (16%) had 3 nodes, and 12 (24%) had 4 or more suspicious nodes. The last ultrasound scan performed during or after NAC showed no nodal response or progression in 10% (n = 5), improvement but not normalization in 33% (n = 16), and normalization in 57% (n = 28); it was not performed in 1 case. The last recorded size of the clipped node ranged from 0.4 to 4 cm with a mean size of 1.3 cm.
Of the 50 patients, 14 (28%) converted to a pathologically node-negative status. The proportion achieving a nodal pathologic complete response varied by tumor subtype from 19% for hormone receptor-positive/ HER2-negative tumors to 75% for hormone receptornegative/HER2-negative tumors. The needle aspirate was nondiagnostic in 4 patients (1 pathologically node-negative and 3 node-positive). Of the 36 patients (72%) with residual disease on surgical pathology, 3 (8%) had a nondiagnostic aspirate, carcinoma was seen in 14 (39%), and 19 (53%) had a false-negative result. Overall, 8% (4 of 50) had a nondiagnostic result, 54% (27 of 50) had an accurate result (either true-negative or true-positive), and 
Ultrasound Characteristics After NAC
When we looked at ultrasound characterization of the nodal response, all patients (5 of 5) with no response or progression had residual nodal metastasis on surgical pathology. Four of these 5 patients (80%) had a falsenegative FNA result. Among the 16 patients with a partial response on ultrasound, 14 (88%) had residual nodal disease. Four of these patients (28.6%) had false-negative FNA before surgery. Finally, 28 patients had normalization of the nodes on ultrasound, even though 16 (57%) had nodal disease on surgical pathology. Two of these 16 patients had nondiagnostic FNA results, whereas 11 of the remaining 14 (78.6%) had a false-negative FNA biopsy (Fig. 2) . The remaining patient, who did not undergo ultrasound after chemotherapy, had residual nodal disease and nondiagnostic FNA.
Ability of FNA to Detect Residual Disease
We next performed an analysis of patients with residual nodal disease who had a diagnostic FNA biopsy (n = 33) to determine differences between those who had a truepositive biopsy (n = 14) and those who had an inaccurate false-negative result (n = 19). The FNR for FNA biopsy in this group was 57.6% (95% CI, 39.2%-74.5%). When we compared patients with a true-positive result and those with a false-negative result, the groups were similar in the clinical T categories, tumor histology, number of suspicious nodes on pre-NAC ultrasound, size of the clipped node on post-NAC ultrasound, and number of positive nodes on surgical pathology. However, patients with accurate FNA had a larger clipped node before initiating chemotherapy (mean, 2.5 vs 1.6 cm; P = .015) and a larger focus of disease in the clipped node after NAC (1.2 vs 0.6 cm; P = .006). Although it did not reach statistical significance, patients with a false-negative result were more likely to have normalization of the nodes on ultrasound (58% [11 of 19] ) than those with a true-positive result (21.4% [3 of 14] ; P = .22). These results are summarized in Table 2 . In a univariate analysis, the odds of a true-positive biopsy result increased significantly with the size of the clipped node before NAC (odds ratio [OR], 4.3; P = .004) and the size of the metastatic focus after NAC (OR, 1.3; P = .003). Postchemotherapy ultrasound evaluations showing normalization (OR, 0.1) or progression (OR, 0.1) were associated with a false-negative FNA biopsy result (P = .013). The sample size limited the multivariate analysis (Table 3) .
DISCUSSION
This trial evaluated the use of FNA of lymph nodes with biopsy-confirmed metastasis to assess responses to NAC. We found that FNA has an FNR of 57.6% and a negative predictive value of 40.6%, and this makes it unreliable for nodal assessment. We can conclude from these data that negative FNA findings after chemotherapy are noninformative. This highlights the need for surgical staging of the axilla after chemotherapy. The use of needle biopsy to assess a patient for nodal disease has allowed for improved multidisciplinary management of patients with breast cancer because nodal disease often determines the need for chemotherapy, the extent of surgery, and the possibility of adjuvant radiation. This has been studied extensively in the diagnostic setting before the initiation of therapy. The use of a physical examination alone is unreliable, with reported FNRs of 30% to 50%, 4, 16 and ultrasound has emerged as a preferred technique for nodal assessment before therapy. One benefit of ultrasound is that abnormal nodes can be assessed in the same setting with needle biopsy to allow for pathologic confirmation of disease. In a study from our institution, axillary ultrasound with FNA of abnormal nodes was found to have a sensitivity of 93% in patients with metastatic deposits measuring >5 mm but a sensitivity of 44% when the largest focus was <5 mm. 1 Another study of FNA showed that the overall sensitivity was 65%, with 82% of the false-negative cases occurring when the metastatic focus was <1 cm. 3 It has been hypothesized that ultrasound could be used to assess nodal responses because some nodes will resume a normal appearance after chemotherapy. A central review of postchemotherapy axillary ultrasound images was performed for patients enrolled in the ACOSOG Z1071 trial. Among patients with normal-appearing nodes after chemotherapy, 57% (243 of 430) were found to have residual nodal disease. 9 This is similar to our finding that 57% of the patients with normalization on ultrasound had disease on surgical pathology. In contrast, 28% of the patients (51 of 181) in the ACOSOG Z1071 trial who had persistently abnormal-appearing nodes on ultrasound were found to be node-negative at the time of surgery. 17 Thus, relying on ultrasound would have committed a significant proportion of women to potentially unnecessary axillary surgery. The Sentinel Neoadjuvant (SENTINA) trial had similar findings. In that trial, a physical examination alone had a sensitivity of 8.3%, a specificity of 94.8%, and a negative predictive value of 46.6%. The addition of an ultrasound assessment improved the sensitivity to 24.4% and the negative predictive value slightly to 50.3%, but the specificity was lowered to 91.4%. In patients with normalized nodes on ultrasound, 49.7% (294 of 592) were pathologically node-positive. 18 These trials support our finding that ultrasound findings are not adequate for the assessment of a nodal response.
One significant finding from the ACOSOG Z1071 trial is that there may be utility to marking nodes with confirmed metastasis with clips before chemotherapy. 
FNA Results
Cancer February 1, 2019 In that trial, 170 patients had a clip placed to mark the node with biopsy-proven disease. When the clipped node was retrieved as an SLN, the FNR was 6.8%, whereas it was 19% when the clipped node was not retrieved as an SLN. 10 In a study from our institution that enrolled patients who had biopsy-confirmed nodal metastasis with a clip placed to mark the biopsied node, a specific evaluation of that node after chemotherapy resulted in an FNR of 4.2%. 11 When a specific evaluation of the clipped node was combined with an evaluation of the sentinel nodes, this FNR fell to 1.4%. In 23% of the cases, the clipped node was not retrieved as a sentinel node, and this highlights the need for specific marking and retrieval of this node in an axillary evaluation. 11 Building on this concept, we developed a surgical technique called targeted axillary dissection, which involves selectively removing the clipped node in addition to removal of the sentinel nodes. 13 To accomplish this, the clipped node is marked with a seed under ultrasound guidance up to 5 days before surgery. The surgeon can then use a Neoprobe to identify the node as well as the sentinel nodes for removal. In the first published series using this procedure, which included 85 patients, the FNR was 2%. 11 Other groups have been evaluating this technique as well, including Diego et al, 19 who reported on 29 patients with successful localization and removal of the clipped node in addition to SLND. For the 11 patients with residual nodal disease, all had disease seen in the clipped node. Investigators from the Mayo clinic have also published a series of 56 patients with clipped nodes removed with a variety of techniques. 20 A group from the Netherlands has used the procedure of marking axillary nodes with radioactive iodine seeds, which involves placing the seed at the time of the initial biopsy. They reported an FNR Cancer February 1, 2019 of 7% in their first 100 patients. 21 To date, they have not published on this technique in addition to SLND; however, trials to assess this are ongoing. 22 This study used FNA instead of the larger sampling possible with core-needle biopsy. In studies of pretherapy nodal assessment, core-needle biopsy had sensitivity and specificity similar to those of FNA. 23, 24 Although accuracy may improve with a larger volume of tissue, we felt that the core-needle approach is problematic in this setting. First, nodes that have a treatment effect after NAC tend to contract and become fibrotic and dense. This makes core-needle biopsy technically more difficult. Second, all of these patients were having I 125 seeds placed in the nodes in preparation for surgery in the following days. The increased tissue trauma associated with a core-needle assessment would have created hematomas that could have potentially complicated the accurate placement of the I 125 seeds and may have resulted in removal of the clip; this would have made it impossible to confirm that the node removed at surgery was the one originally marked with a clip. Lastly, in planning the trial, we felt that FNA would be optimal from a workflow perspective if this had been a positive trial. FNA allows for immediate cytological assessment, so the decision to place or not place an I 125 seed could be made in the same setting. Core biopsy would have required the biopsy to be performed in 1 setting, a wait time of 24 to 48 hours for a pathologic assessment, and then another procedure if the decision to place an I 125 seed was made. The pathologic evaluation of nodes after chemotherapy can be challenging. This study used conventional cytopathologic criteria for classifying specimens as described in the Materials and Methods section. Cytomorphological changes in tumor cells that are commonly noted after therapy, such as pleomorphism, a prominent nucleolus, and vacuolated cytoplasm, were Cancer February 1, 2019 not felt to affect the identification of residual metastasis. We hypothesize that that therapy-related fibrosis seen in nodes resulted in decreased cellularity, which contributed to the high FNR. Though reporting negative results, this trial is relevant for several reasons. First, this is one of the first protocols with the ability to correlate the radiologic appearance and surgical pathology of the specific node known to harbor disease at the time of diagnosis. Most other reports use the pathologic assessment of all axillary nodes removed at surgery as a comparable standard. This also allows for the specific evaluation of the accuracy of needle biopsy in a specific lymph node. Second, as the field moves toward minimizing breast and axillary surgery in patients who undergo NAC, it is important to understand the limitations of a preoperative nodal assessment after NAC; this is the first trial to assess the use of FNA of nodes after NAC. 25 There are additional limitations to this study, including the small sample size and the fact that it is a single-institution study. A selection bias is also possible because potential participants were identified by the treating surgeons. Lastly, although each FNA procedure was performed under ultrasound guidance with visualization of the clipped node, there is a small possibility that another nonclipped node could have been sampled, and this could have led to falsenegative results.
In conclusion, the goal of this study was to determine whether FNA of the clipped node after NAC could reliably identify patients with persistent nodal disease. We have shown that FNA is not accurate in this setting and would misclassify more than 50% of patients with residual nodal disease. This highlights the continued need for surgical evaluation of the axilla with SLND, targeted axillary dissection, or complete axillary node dissection after chemotherapy.
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